Cargando…

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis

OBJECTIVES: To compare the in vitro and in vivo activities of a 4:1 (w/w) fosfomycin/tobramycin combination (FTI) with those of fosfomycin and tobramycin alone against cystic fibrosis (CF) and non-CF bronchiectasis pathogens. METHODS: Clinical isolates of CF Pseudomonas aeruginosa, Staphylococcus au...

Descripción completa

Detalles Bibliográficos
Autores principales:	MacLeod, David L., Barker, Lynn M., Sutherland, Jennifer L., Moss, Suzanne C., Gurgel, Jesse L., Kenney, Thomas F., Burns, Jane L., Baker, William R.
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2009
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740636/ https://www.ncbi.nlm.nih.gov/pubmed/19679597 http://dx.doi.org/10.1093/jac/dkp282

Ejemplares similares

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Comparing inhaled colistin with inhaled fosfomycin/tobramycin as an adjunctive treatment for ventilator‐associated pneumonia: An open‐label randomized controlled trial
por: Hakamifard, Atousa, et al.
Publicado: (2023)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients
por: Hoppentocht, Marcel, et al.
Publicado: (2016)

Cost Reduction of Inhaled Tobramycin by Use of Preservative-Free Intravenous Tobramycin Given via Inhalation
por: Gauthier, Timothy P., et al.
Publicado: (2015)

Adherence with tobramycin inhaled solution and health care utilization
por: Briesacher, Becky A, et al.
Publicado: (2011)

Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis
por: Terpstra, Lotte C., et al.
Publicado: (2022)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Collateral Sensitivity to Fosfomycin of Tobramycin-Resistant Mutants of Pseudomonas aeruginosa Is Contingent on Bacterial Genomic Background
por: Genova, Roberta, et al.
Publicado: (2023)

Efficacy of inhaled tobramycin in severe nosocomial pneumonia
por: Kuzovlev, A, et al.
Publicado: (2012)

Inhaled tobramycin for the treatment of nosocomial pneumonia in sepsis
por: Kuzovlev, A, et al.
Publicado: (2014)

Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?
por: Karki, Kumar, et al.
Publicado: (2021)

Early preventive administration of inhaled tobramycin in severe polytrauma
por: Kuzovlev, A, et al.
Publicado: (2015)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant Pseudomonas aeruginosa
por: Yang, Xuan, et al.
Publicado: (2018)

Resistance Development of Cystic Fibrosis Respiratory Pathogens When Exposed to Fosfomycin and Tobramycin Alone and in Combination under Aerobic and Anaerobic Conditions
por: McCaughey, Gerard, et al.
Publicado: (2013)

Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis
por: Henkle, Emily, et al.
Publicado: (2022)

Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2023)

Inhaled Corticosteroids and Bronchiectasis: Friend or Foe?
por: Martinez-Garcia, Miguel Angel
Publicado: (2023)

Risk of Development of Resistance in Patients with Non-Cystic Fibrosis Bronchiectasis Treated with Inhaled Antibiotics
por: Regan, Kate H., et al.
Publicado: (2018)

Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis
por: Xu, Meng-Jiao, et al.
Publicado: (2020)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Antibacterial Efficacy of Liposomal Formulations Containing Tobramycin and N-Acetylcysteine against Tobramycin-Resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii
por: Alarfaj, Reem E., et al.
Publicado: (2022)

Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem–Resistant Acinetobacter baumannii
por: Nwabor, Ozioma F., et al.
Publicado: (2021)

Exacerbation of chronic renal failure because of inhaled tobramycin in a lung transplant patient
por: Mora Cuesta, Víctor M., et al.
Publicado: (2022)

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
por: Greenwood, James, et al.
Publicado: (2017)

The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol
por: Terpstra, L.C., et al.
Publicado: (2022)

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
por: Hamed, Kamal, et al.
Publicado: (2017)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis
por: Dhand, Rajiv
Publicado: (2018)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Exploring Antibiotic-Potentiating Effects of Tobramycin–Deferiprone Conjugates in Pseudomonas aeruginosa
por: Gandhi, Karan, et al.
Publicado: (2023)

Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms
por: Armijo, Leisha M., et al.
Publicado: (2020)

Structural Basis of Regiospecificity of a Mononuclear Iron Enzyme in Antibiotic Fosfomycin Biosynthesis
por: Yun, Danny, et al.
Publicado: (2011)

Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics
por: Seok, Hyeri, et al.
Publicado: (2020)

Inhaled Antibiotics in Non-cystic Fibrosis Bronchiectasis (NCFB): A Systematic Review of Efficacy and Limitations in Adult Patients
por: Amjad, Zainab, et al.
Publicado: (2022)

Trimeric Tobramycin/Nebramine Synergizes β-Lactam Antibiotics against Pseudomonas aeruginosa
por: Dhiman, Shiv, et al.
Publicado: (2023)

The Impact of the Antibiotic Fosfomycin on Wastewater Communities Measured by Flow Cytometry
por: Li, Shuang, et al.
Publicado: (2022)

The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic
por: Cao, Yingying, et al.
Publicado: (2019)

Bordetella bronchiseptica in non-cystic fibrosis bronchiectasis
por: Karamooz, Elham, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_glr136lo07j9mj238mt67iphim